GlassScriptPhysician profile
Omar J Farhat
NPI 1912529959
$2,727.80
in general payments reported to CMS, 2019-2025
10 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $260 · 2023: $415 · 2024: $717 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,026.90 | 2021-2025 | Idosetr, Idose, Istent Infinite |
| Alcon Vision LLC | $454.32 | 2022-2025 | Clareon, Argos, Hydrus Microstent |
| Sight Sciences, INC. | $440.68 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $167.19 | 2025 | Clearpath, Ahmed Glaucoma Valve, Via360 |
| Abbvie INC. | $153.34 | 2025 | |
| Amgen INC. | $124.99 | 2024 | Uplizna |
| Horizon Therapeutics Plc | $113.66 | 2021 | |
| Allergan, INC. | $99.99 | 2021 | |
| Merz Pharmaceuticals, LLC | $99.15 | 2024 | Xeomin |
| Oyster Point Pharma, INC. | $47.58 | 2024 | Tyrvaya, Ryzumvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.